Researchers discover possible biomarker and therapeutic target for melanoma

Mar 17, 2011

Researchers at Boston University School of Medicine (BUSM), in collaboration with Johns Hopkins University, have identified a potential new biomarker and therapeutic target for melanoma. The novel cell screening method used in the study also clarifies the process behind tumor metastasis and may allow the identification of biomarkers for other aggressive cancers. The findings now appear online in Cancer Research.

According to the American Cancer Society melanoma is the most serious type of and one in 55 people will be diagnosed with it during their lifetime. Previous research has found that metastasis causes more than 90 percent of solid tumor deaths throughout the world and is particularly aggressive in melanoma.

The researchers investigated the process through which melanoma cells communicate with blood vessel cells and promote the formation of tube-like conduits that may allow for . With the combined expertise of the biologists and biomedical engineers they used microfluidics technology to identify molecules that were essential to this communication process. They found that the molecule Neuropilin-2 played a large role in the process and that silencing it inhibited cancer cell growth.

"We found that Neuropilin is an important mediator of melanoma cell and blood vessel cell interactions," said Rhoda Alani, MD, BUSM professor and Chair of Dermatology. "We can now investigate this molecule as a potential and melanoma treatment target. We can also use the unique methodology developed in these studies to evaluate cellular crosstalk between other tumor cell types and vessel cells. Such studies are likely to provide important insights into the metastatic process for other cancers."

According to the researchers the cell-to-cell communication process necessary for metastasis of tumors has garnered much attention recently but detailed knowledge of its underlying is lacking. These findings clarify this process in melanoma tumors and support the use of the team's methods to discover novel factors controlling cell communication for a variety of malignances.

Explore further: AstraZeneca cancer drug, companion test approved

Provided by Boston University Medical Center

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Melanoma uses body's immune system to spread to lungs

Sep 24, 2010

(PhysOrg.com) -- The way melanoma cells use the immune system to spread and develop into lung tumors may lead to a therapy to decrease development of these tumors, according to Penn State researchers.

Gene signature spells poor outcome

Aug 30, 2007

Other than visually inspecting the disease, doctors have no genetic blueprint to classify melanomas, a lethal form of skin cancer. Tumors generally are ranked by how deeply the growth has invaded underlying skin tissue. ...

Protein targeted to stop melanoma tumor growth

Dec 09, 2010

Halting the growth of melanoma tumors by targeting the MIC-1 protein that promotes blood vessel development in tumors may lead to better treatment of this invasive and deadly cancer, according to Penn State College of Medicine ...

Recommended for you

Putting the brakes on cancer

Dec 19, 2014

A study led by the University of Dundee, in collaboration with researchers at our University, has uncovered an important role played by a tumour suppressor gene, helping scientists to better understand how ...

Peanut component linked to cancer spread

Dec 19, 2014

Scientists at the University of Liverpool have found that a component of peanuts could encourage the spread and survival of cancer cells in the body.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.